Critical need for pharmacologic treatment options in NAFLD: A pediatric perspective

Clin Transl Sci. 2021 May;14(3):781-783. doi: 10.1111/cts.12952. Epub 2021 Jan 21.


Nonalcoholic fatty liver disease (NAFLD) affects up to 70% of children with obesity and has become the number one etiology for liver transplant in the United States. Early, effective intervention is critical to prevent disease progression into adulthood. Yet, it is seldom achieved through lifestyle modification alone. Thus, children must be included in NAFLD pharmacology trials, which, to date, continue to focus primarily on adult populations. This commentary serves as a call to action.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Age Factors
  • Child
  • Clinical Trials as Topic
  • Disease Progression
  • End Stage Liver Disease / pathology
  • End Stage Liver Disease / prevention & control*
  • Humans
  • Non-alcoholic Fatty Liver Disease / drug therapy*
  • Non-alcoholic Fatty Liver Disease / etiology
  • Non-alcoholic Fatty Liver Disease / pathology
  • Patient Selection*
  • Pediatric Obesity / complications*
  • Pediatric Obesity / drug therapy